Jones George Patrick 4

What Happened
George Patrick Jones, Chief Commercial Officer of Biofrontera, was granted two compensation awards on March 4, 2026: a 50,000-share option grant and 50,000 restricted stock units (RSUs). Both awards are reported as derivative acquisitions at $0.00 per share (awarded for no cash consideration). The option vests in two equal installments (Sept 4, 2026 and March 4, 2027). The RSUs vest in two equal yearly installments beginning March 4, 2027 and, at the company's discretion, will be settled in shares, cash, or a mix within 60 days after vesting.

Key Details

• Transaction date: March 4, 2026; filing date: March 6, 2026 (filed promptly).
• Awards: 50,000 options (derivative) + 50,000 RSUs (derivative); grant price reported as $0.00 (awarded).
• Shares owned after transaction: not specified in the excerpt of the filing.
• Vesting: Options vest in two equal installments (Sept 4, 2026; Mar 4, 2027). RSUs vest in two equal annual installments starting Mar 4, 2027; settlement (shares/cash) within 60 days of vesting.
• Footnotes: F1 describes option vesting; F2/F3 describe RSU terms and discretionary cash/share settlement; F4 notes other options with different terms are not included.
• Transaction code: A (award/grant). This is a compensation grant, not a market purchase or sale.

Context
These awards are typical executive compensation grants intended to retain management and align incentives. They do not represent an immediate stock purchase or sale and only translate into economic value over time according to vesting and settlement terms. Options generally have value only if the stock price exceeds the exercise price (exercise price not shown in this excerpt); RSUs convert to shares or cash per the company’s settlement choice.